|
End-of-day quote
TEL AVIV STOCK EXCHANGE
30/10/2026
|
5-day change | 1st Jan Change | ||
| 1,792.00 ILa | +1.70% |
|
-2.40% | - |
| 14/07 | Rafa Laboratories Ltd. has completed an IPO in the amount of ILS 549.8718 million. | CI |
| 09/07 | Rafa Laboratories Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
TEL AVIV STOCK EXCHANGEILa
| Markets | Quality | ||
|---|---|---|---|
TEL AVIV STOCK EXCHANGE
| RAFA | End-of-day quote | |
TEL AVIV STOCK EXCHANGE
| RAFA | Delayed |
| 1 day | +1.70% | ||
| 1 week | -2.40% | ||
| Current month | -1.05% | ||
| 1 month | +0.39% | ||
| 3 months | +12.21% |
| 1 week | 1,671 |  | 1,865 |
| 1 month | 1,577 | | 1,868 |
| Current year | 1,401 | | 1,999 |
| 1 year | 1,401 | | 1,999 |
| 3 years | 1,401 | | 1,999 |
| 5 years | 1,401 | | 1,999 |
| 10 years | 1,401 | | 1,999 |
| Manager | Title | Age | Since |
|---|---|---|---|
Ido Leshem
CEO | Chief Executive Officer | 50 | 01/01/2024 |
Gabi Hazan
COO | Chief Operating Officer | 58 | 01/01/2007 |
Yael Paula Tomer
CTO | Chief Tech/Sci/R&D Officer | 56 | - |
| Director | Title | Age | Since |
|---|---|---|---|
Gillon Beck
BRD | Director/Board Member | 64 | 31/12/2020 |
Abraham Dadon
BRD | Director/Board Member | 70 | 27/05/2026 |
Amir Levin
BRD | Director/Board Member | 60 | 26/06/2007 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.70% | -2.40% | - | - | 55Cr | |
| +3.19% | +8.48% | +74.25% | +153.03% | 1,22400Cr | |
| -0.73% | +2.09% | +46.41% | +87.64% | 66TCr | |
| +1.41% | +3.40% | +30.98% | +112.26% | 51TCr | |
| +0.42% | +2.88% | +54.92% | +69.67% | 39TCr | |
| +2.18% | +1.55% | +72.70% | +45.42% | 36TCr | |
| +1.12% | +3.80% | +35.82% | +59.72% | 30TCr | |
| +6.96% | +7.55% | +11.15% | +37.89% | 27TCr | |
| +1.15% | +4.19% | +59.72% | +78.16% | 25TCr | |
| +3.06% | +8.58% | +44.03% | +122.76% | 21TCr | |
| Average | +1.73% | +2.00% | +47.77% | +85.17% | 41.77TCr | |
| Weighted average by Cap. | +1.17% | +3.04% | +53.35% | +100.42% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 42Cr 0 13Cr 12Cr 11Cr 9.98Cr 19Cr 1.27TCr 19Cr 131.29Cr 53Cr 667.51Cr 50Cr 49Cr 2.11TCr | 42Cr 0 13Cr 12Cr 11Cr 9.94Cr 19Cr 1.26TCr 19Cr 130.78Cr 52Cr 664.89Cr 50Cr 49Cr 2.1TCr |
| Net income | 9.94Cr 0 3.16Cr 2.83Cr 2.61Cr 2.36Cr 4.41Cr 300.35Cr 4.5Cr 31Cr 12Cr 157.99Cr 12Cr 12Cr 498.25Cr | 10Cr 0 3.19Cr 2.86Cr 2.63Cr 2.38Cr 4.45Cr 303.09Cr 4.54Cr 31Cr 13Cr 159.43Cr 12Cr 12Cr 502.79Cr |
| Net Debt | - | - |
Employees
257
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/26/30 | ILA 1,792.00 | +1.70% | 3,475 |
| 29/26/29 | ILA 1,762.00 | +0.11% | 5,431 |
| 28/26/28 | ILA 1,760.00 | -5.12% | 12,581 |
| 26/26/26 | ILA 1,855.00 | +0.05% | 37,374 |
| 23/26/23 | ILA 1,854.00 | +0.98% | 1,760 |
- Stock Market
- Stocks
- RAFA Stock
Select your edition
All financial news and data tailored to specific country editions
